GC Biopharma, a provider of biopharmaceutical products, said that the World Health Organization (WHO) awarded prequalification for its fill-finish plant in Ochang, South Korea.

“We hope to contribute to advancing global public health based on our know-how and manufacturing capabilities that have produced and supplied vaccines for half a century,” said EC Huh, president of GC Biopharma.

The plant, established in 2019, is the largest fill-finish facility in South Korea, according to the company.

GC Biopharma installed an isolator-facilities and applied a single-use system at the site, which features state-of-the-art technology that automates the entire process from raw material warehousing to production and shipment.

The facility can produce 300 million doses annually enabling contract manufacturing organizations (CMOs) of drug products (DP) for vaccines (sterile vials and prefilled syringe), and non-vaccine fill-finish and packaging.

GC Biopharma supplies a large amount of seasonal flu vaccines every year through PAHO (Pan American health Organization) and UNICEF under the WHO and has been supplying more than 50 million doses of flu vaccines even in the COVID-19 pandemic situation for the past three years.